You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 25, 2025

Patent: 10,092,645


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,092,645
Title:Methods of treatment with antagonists against PD-1 and PD-L1 in combination with radiation therapy
Abstract: This application provides a method of treating cancer in a patient comprising administering at least one dose of radiation therapy and at least one PD-1 and/or PD-L1 antagonist, wherein at least one PD-1 and/or PD-L1 antagonist is administered on the same day as a dose of radiation therapy or up to and including 4 days later.
Inventor(s): Stewart; Ross (Cambridge, GB), Morrow; Michelle (Cambridge, GB), Wilkinson; Robert (Cambridge, GB), Poon; Edmund (Cambridge, GB), Dovedi; Simon (Manchester, GB), Illidge; Tim (Manchester, GB)
Assignee: MedImmune Limited (Cambridge, GB)
Application Number:14/740,876
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

Analyzing the Claims and Patent Landscape of United States Patent 10,092,645

Introduction

Understanding the claims and patent landscape of a specific patent, such as United States Patent 10,092,645, involves a detailed examination of several key aspects. This includes the patent's subject matter, the claims made, the technological context, and the broader patent landscape. Here, we will delve into these areas to provide a comprehensive and critical analysis.

Understanding the Patent System

Before diving into the specifics of the patent, it is crucial to understand the broader patent system. Patents are primary indicators of invention, providing exclusive rights to inventors for their creations. The U.S. Patent and Trademark Office (USPTO) classifies patents into various technology areas, which helps in analyzing trends and focus areas in patenting[1].

Subject Matter Eligibility

A critical aspect of any patent is its subject matter eligibility. Under 35 U.S.C. § 101, a claimed invention must fall within one of the four statutory categories: process, machine, manufacture, or composition of matter. Additionally, it must not be directed to judicial exceptions such as abstract ideas, laws of nature, or natural phenomena unless the claim includes additional limitations that amount to significantly more than the exception[4].

The Two-Pronged Framework for AI Inventions

For patents involving AI, such as those that might be related to the technology area of the patent in question, the 2024 Guidance Update emphasizes the importance of Prong Two of Step 2A. This involves demonstrating that the claims are directed to a specific, concrete technological advancement or solution to a technical problem. This is particularly relevant for overcoming section 101 rejections[3].

Claims Analysis

The claims of a patent are its most critical component, as they define the scope of the invention. The number of claims and their complexity have been increasing over the years. For instance, patent applications now often include hundreds or even thousands of claims, necessitating automated systems for claims analysis to manage this complexity[2].

Automated Claims Analysis

Tools like the Patent Claims Analysis System and Method (US20110138338A1) have been developed to facilitate the review of patent claims. These systems automate the import of patent claims, parse them hierarchically, and provide interactive diagrams for easier comprehension. This is essential given the growing number of patent applications and the increasing complexity of claims[2].

Patent 10,092,645: A Case Study

To analyze the specific patent, we need to look at its claims, the technology area it belongs to, and how it fits into the broader patent landscape.

Technology Area

The patent's technology area is crucial for understanding its context. For example, if it falls under electrical engineering or computer technology, it would be part of a sector that has seen significant growth in recent years. The USPTO data shows that electrical engineering patents more than doubled between 2000 and 2018, driven in part by advancements in information and communication technologies (ICT)[1].

Claims Specificity and Utility

Each claim must be specific, substantial, and credible. The utility of the invention must be apparent, and it must not fall under judicial exceptions unless it includes additional limitations. A rejection under 35 U.S.C. § 101 for lack of utility can occur if the applicant fails to identify any specific and substantial utility or if the asserted utility is not credible[4].

Comparative Analysis

Comparing the claims of Patent 10,092,645 with other patents in the same technology area can provide insights into its uniqueness and the competitive landscape. This involves analyzing the hierarchical structure of the claims, the number of claims, and how they are presented to ensure they are not overly broad or too narrow.

Practical Applicability and Technological Advancement

For patents facing section 101 rejections, demonstrating practical applicability and a specific technological advancement is crucial. This involves showing that the claims are directed to solving a real-world problem or providing a concrete technological solution. This approach helps in overcoming rejections and ensuring the patent's validity[3].

Double Patenting Prohibition

It is also important to ensure that the patent does not fall under the double patenting prohibition. This means that the same invention cannot be patented more than once by the same inventor or by different inventors with a common applicant or assignee[4].

Trends in Patenting

The broader patent landscape is influenced by trends in technology innovation. The increase in patent applications, particularly in high-technology areas, is driven by the need for patent protection to attract capital for development and commercialization. Technologies like word processing and remote electronic database searching have facilitated this process, making it easier to file and manage patent applications[2].

Key Takeaways

  • Subject Matter Eligibility: Ensure the patent falls within statutory categories and avoids judicial exceptions.
  • Claims Analysis: Use automated systems to manage complex claims hierarchies.
  • Practical Applicability: Demonstrate specific technological advancements to overcome section 101 rejections.
  • Double Patenting: Avoid claiming the same invention multiple times.
  • Technology Trends: Understand the growth in patent applications and the role of ICT in driving these trends.

FAQs

What is the significance of subject matter eligibility in patent law?

Subject matter eligibility ensures that a claimed invention falls within one of the four statutory categories (process, machine, manufacture, or composition of matter) and is not directed to judicial exceptions unless it includes additional limitations.

How do automated claims analysis systems help in patent review?

Automated claims analysis systems facilitate the review of patent claims by importing, parsing, and hierarchically organizing claims, making it easier to manage complex patent applications.

What is the importance of Prong Two of Step 2A in AI inventions?

Prong Two of Step 2A is crucial for AI inventions as it requires demonstrating that the claims are directed to a specific, concrete technological advancement or solution to a technical problem, helping to overcome section 101 rejections.

Why is it important to avoid double patenting?

Double patenting prohibition ensures that the same invention is not patented more than once by the same inventor or by different inventors with a common applicant or assignee, preventing redundant and overlapping patents.

How has technology innovation impacted the patent landscape?

Technology innovation has driven an increase in patent applications, particularly in high-technology areas, and has been facilitated by advancements in tools like word processing and remote electronic database searching.

Sources

  1. Invention: U.S. and Comparative Global Trends. National Science Foundation. Retrieved from https://ncses.nsf.gov/pubs/nsb20204/invention-u-s-and-comparative-global-trends
  2. US20110138338A1 - Patent Claims Analysis System and Method. Google Patents. Retrieved from https://patents.google.com/patent/US20110138338A1/en
  3. The Importance of Prong Two of Step 2A for AI Inventions. Baker Botts. Retrieved from https://www.bakerbotts.com/thought-leadership/publications/2024/september/the-importance-of-prong-two-of-step-2a-for-ai-inventions
  4. 2104-Requirements of 35 U.S.C. 101. USPTO. Retrieved from https://www.uspto.gov/web/offices/pac/mpep/s2104.html

More… ↓

⤷  Try for Free

Details for Patent 10,092,645

ApplicantTradenameBiologic IngredientDosage FormBLAApproval DatePatent No.Expiredate
Merck Sharp & Dohme Llc KEYTRUDA pembrolizumab For Injection 125514 September 04, 2014 10,092,645 2034-06-17
Merck Sharp & Dohme Llc KEYTRUDA pembrolizumab Injection 125514 January 15, 2015 10,092,645 2034-06-17
Bristol-myers Squibb Company OPDIVO nivolumab Injection 125554 December 22, 2014 10,092,645 2034-06-17
Bristol-myers Squibb Company OPDIVO nivolumab Injection 125554 October 04, 2017 10,092,645 2034-06-17
Bristol-myers Squibb Company OPDIVO nivolumab Injection 125554 August 27, 2021 10,092,645 2034-06-17
>Applicant>Tradename>Biologic Ingredient>Dosage Form>BLA>Approval Date>Patent No.>Expiredate
Showing 1 to 5 of 5 entries

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.